Clinical Trials Browser

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

NCT00680901 2025-08-07

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Phase 3 Completed

545 enrolled 24 charts

Gastrointestinal

Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02872116 2025-08-07

CheckMate649

Phase 3 Completed

2,031 enrolled 19 charts 1 FDA

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT03783442 2025-07-29

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Phase 3 Completed

649 enrolled 22 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07025239 2025-06-17

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

Phase 3 Not yet recruiting

430 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03478488 2025-05-29

KN035-BTC

Phase 3 Active not recruiting

480 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT06792253 2025-01-24

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 3 Recruiting

416 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04210115 2024-11-15

KEYNOTE 975

Phase 3 Active not recruiting

703 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT05144854 2024-09-05

A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Phase 3 Active not recruiting

626 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05751850 2024-05-09

HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

Phase 3 Recruiting

778 enrolled

Gastrointestinal

First-line Treatment of Advanced Pancreatic Cancer

NCT03006705 2024-05-03

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

Phase 3 Completed

800 enrolled

Gastrointestinal

Stomach Neoplasms

NCT01515748 2023-12-13

PRODIGY

Phase 3 Completed

530 enrolled 11 charts

Gastrointestinal

Stomach Neoplasms

NCT02394795 2023-11-01

PARADIGM

Phase 3 Completed

823 enrolled 20 charts

Gastrointestinal

Colorectal Neoplasms

NCT03745170 2023-03-01

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

Phase 3 Completed

650 enrolled

Gastrointestinal

Stomach Neoplasms

NCT03504423 2023-01-03

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Phase 3 Completed

528 enrolled 11 charts

Gastrointestinal

Pancreatic Cancer Metastatic

NCT02625610 2022-06-09

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Phase 3 Completed

499 enrolled 22 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT02322593 2021-12-20

SOLAR

Phase 3 Completed

711 enrolled 16 charts

Gastrointestinal

Gastrointestinal Diseases, Gastrointestinal Neoplasms, Stomach Neoplasms

Clinical Trials

MOUNTAINEER-03

LUCERNA

MK-3475-C66

KEYNOTE-585

NAPOLI 3

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

SUNMO

STAR-221

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

EPCORE DLBCL-4

HARMONi-GI3

HERIZON-GEA-01

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Spotlight

A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL

GLOW

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

LOTIS 5

Beacon-BTC

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

POLARGO

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

MK-7902-014

RASolute 302

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

CheckMate 8HW

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

COMPOSE

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

CheckMate649

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

KN035-BTC

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

KEYNOTE 975

A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

PRODIGY

PARADIGM

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

SOLAR